Michael Gelband’s Immunovant IMVT Stock Holding History

Michael Gelband’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-107,300	Closed	-$1.13M	–	2361
2021 Q2	$1.13M	Buy	+107,300	New	+$1.5M	0.01%	944

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Michael Gelband's IMVT Position: Q2 2026 in Review

Michael Gelband sold out of Immunovant (IMVT) in Q2 2026, closing a stake of 21,941 shares — an estimated $545K sold.

Michael Gelband first reported a position in IMVT in Q4 2019 and held it in 17 quarters. The position peaked at $3.87M in Q2 2025. 224 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

Michael Gelband reported no remaining Immunovant position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 21,941 Immunovant shares in Q2 2026, an estimated $545K.
Michael Gelband first reported a position in Immunovant in Q4 2019 and held it in 17 quarters.
Michael Gelband's Immunovant position peaked at $3.87M in Q2 2025.
224 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.